ONCAlert | Upfront Therapy for mRCC

ASH CLL Spotlight

A spotlight on chronic lymphocytic leukemia (CLL) from the 2016 ASH Annual Meeting at the San Diego Convention Center in San Diego, California, from December 3 to December 6, 2016.

$High Response Rate With Venetoclax in Relapsed/Refractory CLL$

High Response Rate With Venetoclax in Relapsed/Refractory CLL

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

Nitin Jain, MD

Induction of Ibrutinib Regimen Achieves 100% Response Rate in CLL

Jason M. Broderick

Lenalidomide Maintenance Substantially Improved PFS in High-Risk Subgroup of CLL

Wayne Kuznar

Ibrutinib Shows Impressive 5-Year Results in CLL/SLL

Lauren M. Green

Nivolumab/Ibrutinib Combo Shows Encouraging Activity for Richter Transformation

Silas Inman

ASH CLL Spotlight

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.